Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synthes Charged With Unauthorized Spine Repair Trial, Faces $34 Mil. Fine

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic device maker Synthes and its Norian subsidiary face $34.8 million in potential fines for allegedly skirting FDA requirements and conducting unauthorized clinical trials of their Norian XR and Norian SRS bone cement for vertebral compression fractures

You may also be interested in...



Synthes To Pay $23 Million For Illegal Testing, Marketing Scheme

Orthopedic device maker Synthes and its subsidiary Norian will pay a total of $23.2 million in criminal penalties for conducting unauthorized clinical trials of its Norian XR and Norian SRS bone cement products

Synthes To Pay $23 Million For Illegal Testing, Marketing Scheme

Orthopedic device maker Synthes and its subsidiary Norian will pay a total of $23.2 million in criminal penalties for conducting unauthorized clinical trials of its Norian XR and Norian SRS bone cement products

FDA Targeting Execs With Criminal Charges For Adulterated/Misbranded Goods

FDA increasingly will prosecute corporate officers in response to criticism over the agency's handling of violations of the Federal Food, Drug & Cosmetic Act in recent years

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel